Immunization with host-type CD8α+ dendritic cells reduces experimental acute GVHD in an IL-10-dependent manner

Blood

Volumn 115, Issue 3, 2010, Pages 724-735

  Toubai, Tomomi ^a   Malter, Chelsea ^a   Tawara, Isao ^a   Liu, Chen ^b   Nieves, Evelyn ^a   Lowler, Kathleen P ^a   Sun, Yaping ^a   Reddy, Pavan ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD69 ANTIGEN; CD8ALPHA ANTIGEN; DENDRITIC CELL VACCINE; GAMMA INTERFERON; GLYCOPROTEIN P 15095; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR ALPHA; TRANSCRIPTION FACTOR FOXP3; CD8 ANTIGEN; CD8 ANTIGEN, ALPHA CHAIN;

ACTIVE IMMUNIZATION; ACUTE GRAFT VERSUS HOST DISEASE; ALLOTRANSPLANTATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN SPECIFICITY; ARTICLE; CD4+ CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL CONTACT; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; FEMALE; HOST CELL; IN VITRO STUDY; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; T LYMPHOCYTE; ACUTE DISEASE; ANIMAL; BAGG ALBINO MOUSE; C3H MOUSE; C57BL MOUSE; CELL CULTURE; EVALUATION; GENETICS; GRAFT VERSUS HOST REACTION; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; METABOLISM; METHODOLOGY; PASSIVE IMMUNIZATION; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TRANSPLANTATION;

ACUTE DISEASE; ANIMALS; ANTIGENS, CD8; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; GRAFT VS HOST DISEASE; IMMUNITY, CELLULAR; IMMUNIZATION, PASSIVE; INTERLEUKIN-10; MICE; MICE, INBRED BALB C; MICE, INBRED C3H; MICE, INBRED C57BL; MICE, TRANSGENIC; T-LYMPHOCYTES; TRANSPLANTATION CONDITIONING; TRANSPLANTATION, HOMOLOGOUS;

EID: 77449138878     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2009-06-229708     Document Type: Article

References (59)

1. Nossal GJ. Host immunobiology and vaccine development. Lancet. 1997;350(9087):1316-1319.
2. Banchereau J, Palucka AK. Dendritic cells as therapeutic vaccines against cancer. Nat Rev Immunol. 2005;5(4):296-306. (Pubitemid 40516155)
3. Steinman RM, Hawiger D, Nussenzweig MC. Tolerogenic dendritic cells. Annu Rev Immunol. 2003;21:685-711.
4. Appelbaum FR. Haematopoietic cell transplantation as immunotherapy. Nature. 2001;411(6835): 385-389.
5. Welniak LA, Blazar BR, Murphy WJ. Immunobiology of allogeneic hematopoietic stem cell transplantation. Annu Rev Immunol. 2007;25:139-170. (Pubitemid 46697905)
6. Shlomchik WD, Couzens MS, Tang CB, et al. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science. 1999;285(5426):412-415. (Pubitemid 29343964)
7. Teshima T, Ordemann R, Reddy P, et al. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat Med. 2002;8(6):575-581. (Pubitemid 34633434)
8. Jones SC, Murphy GF, Friedman TM, Korngold R. Importance of minor histocompatibility antigen expression by nonhematopoietic tissues in a CD4+ T cell-mediated graft-versus-host disease model. J Clin Invest. 2003;112(12):1880-1886. (Pubitemid 38063711)
9. Reddy P, Maeda Y, Liu C, Krijanovski OI, Korngold R, Ferrara JL. A crucial role for antigenpresenting cells and alloantigen expression in graft-versus-leukemia responses. Nat Med. 2005; 11(11):1244-1249. (Pubitemid 43093673)
10. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood. 2000;95(8):2484-2490. (Pubitemid 30210524)
11. Auffermann-Gretzinger S, Lossos IS, Vayntrub TA, et al. Rapid establishment of dendritic cell chimerism in allogeneic hematopoietic cell transplant recipients. Blood. 2002;99(4):1442-1448. (Pubitemid 34547103)
12. MacDonald KP, Rowe V, Clouston AD, et al. Cytokine expanded myeloid precursors function as regulatory antigen-presenting cells and promote tolerance through IL-10-producing regulatory T cells. J Immunol. 2005;174(4):1841-1850. (Pubitemid 40223923)
13. Morris ES, MacDonald KP, Hill GR. Stem cell mobilization with G-CSF analogs: a rational approach to separate GVHD and GVL? Blood. 2006;107(9):3430-3435.
14. Chakraverty R, Sykes M. The role of antigenpresenting cells in triggering graft-versus-host disease and graft-versus-leukemia. Blood. 2007; 110(1):9-17. (Pubitemid 47026813)
15. Duffner UA, Maeda Y, Cooke KR, et al. Host dendritic cells alone are sufficient to initiate acute graft-versus-host disease. J Immunol. 2004; 172(12):7393-7398. (Pubitemid 38747600)
16. Merad M, Hoffmann P, Ranheim E, et al. Depletion of host Langerhans cells before transplantation of donor alloreactive T cells prevents skin graft-versus-host disease. Nat Med. 2004;10(5): 510-517. (Pubitemid 38667910)
17. Steinman RM. Dendritic cells in vivo: a key target for a new vaccine science. Immunity. 2008;29(3): 319-324.
18. Steinman RM, Banchereau J. Taking dendritic cells into medicine. Nature. 2007;449(7161):419-426.
19. Melief CJ. Cancer immunotherapy by dendritic cells. Immunity. 2008;29(3):372-383.
20. Banchereau J, Steinman RM. Dendritic cells and the control of immunity. Nature. 1998;392(6673): 245-252.
21. Shortman K, Naik SH. Steady-state and inflammatory dendritic-cell development. Nat Rev Immunol. 2007;7(1):19-30.
22. Morelli AE, Thomson AW. Tolerogenic dendritic cells and the quest for transplant tolerance. Nat Rev Immunol. 2007;7(8):610-621. (Pubitemid 47123548)
23. Vremec D, Zorbas M, Scollay R, et al. The surface phenotype of dendritic cells purified from mouse thymus and spleen: investigation of the CD8 expression by a subpopulation of dendritic cells. J Exp Med. 1992;176(1):47-58.
24. Vremec D, Pooley J, Hochrein H, Wu L, Shortman K. CD4 and CD8 expression by dendritic cell subtypes in mouse thymus and spleen. J Immunol. 2000;164(6):2978-2986. (Pubitemid 30148956)
25. Suss G, Shortman K. A subclass of dendritic cells kills CD4 T cells via Fas/Fas-ligand-induced apoptosis. J Exp Med. 1996;183(4):1789-1796. (Pubitemid 26134319)
26. Maraskovsky E, Brasel K, Teepe M, et al. Dramatic increase in the numbers of functionally mature dendritic cells in Flt3 ligand-treated mice: multiple dendritic cell subpopulations identified. J Exp Med. 1996;184(5):1953-1962. (Pubitemid 26404485)
27. Kronin V, Winkel K, Suss G, et al. A subclass of dendritic cells regulates the response of naive CD8 T cells by limiting their IL-2 production. J Immunol. 1996;157(9):3819-3827. (Pubitemid 126449288)
28. Bilsborough J, George TC, Norment A, Viney JL. Mucosal CD8alpha+ DC, with a plasmacytoid phenotype, induce differentiation and support function of T cells with regulatory properties. Immunology. 2003;108(4):481-492. (Pubitemid 36469686)
29. Pettersson A, Wu XC, Ciumas C, et al. CD8alpha dendritic cells and immune protection from experimental allergic encephalomyelitis. Clin Exp Immunol. 2004;137(3):486-495. (Pubitemid 39128074)
30. Inaba K, Inaba M, Romani N, et al. Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/ macrophage colony-stimulating factor. J Exp Med. 1992;176(6):1693-1702.
31. Teshima T, Reddy P, Lowler KP, et al. Flt3 ligand therapy for recipients of allogeneic bone marrow transplants expands host CD8 alpha(+) dendritic cells and reduces experimental acute graft-versushost disease. Blood. 2002;99(5):1825-1832. (Pubitemid 34533059)
32. Cooke KR, Kobzik L, Martin TR, et al. An experimental model of idiopathic pneumonia syndrome after bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood. 1996; 88(8):3230-3239. (Pubitemid 26357409)
33. Gatza E, Okada CY. Tumor cell lysate-pulsed dendritic cells are more effective than TCR Id protein vaccines for active immunotherapy of T cell lymphoma. J Immunol. 2002;169(9):5227-5235. (Pubitemid 35217194)
34. Reddy P, Teshima T, Kukuruga M, et al. Interleukin-18 regulates acute graft-versus-host disease by enhancing Fas-mediated donor T cell apoptosis. J Exp Med. 2001;194(10):1433-1440. (Pubitemid 33081518)
35. Hill GR, Cooke KR, Teshima T, et al. Interleukin-11 promotes T cell polarization and prevents acute graft-versus-host disease after allogeneic bone marrow transplantation. J Clin Invest. 1998; 102(1):115-123. (Pubitemid 28323837)
36. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, Bhardwaj N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001; 193(2):233-238. (Pubitemid 32524454)
37. Inaba K, Pack M, Inaba M, Sakuta H, Isdell F, Steinman RM. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J Exp Med. 1997;186(5):665-672. (Pubitemid 27381531)
38. den Haan JM, Lehar SM, Bevan MJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J Exp Med. 2000;192(12):1685-1696.
39. Kronin V, Wu L, Gong S, Nussenzweig MC, Shortman K. DEC-205 as a marker of dendritic cells with regulatory effects on CD8 T cell responses. Int Immunol. 2000;12(5):731-735. (Pubitemid 30248906)
40. Belz GT, Behrens GM, Smith CM, et al. The CD8alpha(+) dendritic cell is responsible for inducing peripheral self-tolerance to tissueassociated antigens. J Exp Med. 2002;196(8): 1099-1104.
41. Turnquist HR, Thomson AW. Taming the lions: manipulating dendritic cells for use as negative cellular vaccines in organ transplantation. Curr Opin Organ Transplant. 2008;13(4):350-357.
42. Groux H, O'Garra A, Bigler M, et al. A CD4+ T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature. 1997; 389(6652):737-742. (Pubitemid 27458961)
43. Reddy P, Sun Y, Toubai T, et al. Histone deacetylase inhibition modulates indoleamine 2,3-dioxygenase-dependent DC functions and regulates experimental graft-versus-host disease in mice. J Clin Invest. 2008;118(7):2562-2573.
44. Sato K, Yamashita N, Baba M, Matsuyama T. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity. 2003;18(3):367-379. (Pubitemid 36351516)
45. O'Connell PJ, Li W, Wang Z, Specht SM, Logar AJ, ThomsonAW. Immature and mature CD8alpha+ dendritic cells prolong the survival of vascularized heart allografts. J Immunol. 2002;168(1):143-154. (Pubitemid 34014113)
46. Groux H, Bigler M, de Vries JE, Roncarolo MG. Interleukin-10 induces a long-term antigenspecific anergic state in human CD4+ T cells. J Exp Med. 1996;184(1):19-29. (Pubitemid 26247211)
47. Bacchetta R, Bigler M, Touraine JL, et al. High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. J Exp Med. 1994;179(2):493-502. (Pubitemid 24058737)
48. Weston LE, Geczy AF, Briscoe H. Production of IL-10 by alloreactive sibling donor cells and its influence on the development of acute GVHD. Bone Marrow Transplant. 2006;37(2):207-212. (Pubitemid 43108814)
49. Blazar BR, Taylor PA, Panoskaltsis-Mortari A, et al. Interleukin-10 dose-dependent regulation of CD4+ and CD8+ T cell-mediated graft-versushost disease. Transplantation. 1998;66(9):1220-1229. (Pubitemid 28530328)
50. Markees TG, Phillips NE, Gordon EJ, et al. Longterm survival of skin allografts induced by donor splenocytes and anti-CD154 antibody in thymectomized mice requires CD4(+) T cells, interferongamma, and CTLA4. J Clin Invest. 1998;101(11): 2446-2455.
51. Parker DC, Greiner DL, Phillips NE, et al. Survival of mouse pancreatic islet allografts in recipients treated with allogeneic small lymphocytes and antibody to CD40 ligand. Proc Natl Acad Sci U S A. 1995;92(21):9560-9564.
52. Markees TG, Phillips NE, Noelle RJ, et al. Prolonged survival of mouse skin allografts in recipients treated with donor splenocytes and antibody to CD40 ligand. Transplantation. 1997;64(2):329-335.
53. Iwakoshi NN, Mordes JP, Markees TG, Phillips NE, Rossini AA, Greiner DL. Treatment of allograft recipients with donor-specific transfusion and anti-CD154 antibody leads to deletion of alloreactive CD8+ T cells and prolonged graft survival in a CTLA4-dependent manner. J Immunol. 2000;164(1):512-521.
54. Markees TG, Phillips NE, Gordon EJ, et al. Prolonged skin allograft survival in mice treated with Flt3-ligand-induced dendritic cells and anti-CD154 monoclonal antibody. Transplant Proc. 1999;31(1):884-885.
55. Grigoleit GU, Kapp M, Hebart H, et al. Dendritic cell vaccination in allogeneic stem cell recipients: induction of human cytomegalovirus (HCMV)-specific cytotoxic T lymphocyte responses even in patients receiving a transplant from an HCMVseronegative donor. J Infect Dis. 2007;196(5): 699-704. (Pubitemid 47293851)
56. Bendandi M, Rodriguez-Calvillo M, Inoges S, et al. Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation. Leuk Lymphoma. 2006;47(1): 29-37. (Pubitemid 43101721)
57. Natzke AM, Shaw JL, McKeller MR, Emo KL, Mullen CA. Hematopoietic stem cell recipients do not develop post-transplantation immune tolerance to antigens present on minimal residual disease. Biol Blood Marrow Transplant. 2007;13(1): 34-45.
58. Kitawaki T, Kadowaki N, Kondo T, et al. Potential of dendritic-cell immunotherapy for relapse after allogeneic hematopoietic stem cell transplantation, shown by WT1 peptide- and keyhole-limpethemocyanin-pulsed, donor-derived dendritic-cell vaccine for acute myeloid leukemia. Am J Hematol. 2008;83(4):315-317.
59. Tatsugami K, Eto M, Harano M, et al. Dendriticcell therapy after non-myeloablative stem-cell transplantation for renal-cell carcinoma. Lancet Oncol. 2004;5(12):750-752. (Pubitemid 39646785)